You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Omniphobic Cerebral Shunt to Eliminate Clogging and Dysfunction
SBC: FREEFLOW MEDICAL DEVICES LLC Topic: 106PROJECT SUMMARY Hydrocephalus causes long term neurological problems and patient suffering. Current treatments, most of which involve surgical diversion of cerebrospinal fluid (CSF) with shunt catheters, fail at an alarming rate. Approximately 98% of all shunts fail within 10 years, and this failure rate is the dominant contributor to the $2 billion-per-year cost that hydrocephalus incurs on our h ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Catheter Based Cardiovascular Device Retrieval System
SBC: Onocor LLC Topic: NHLBIRecent advances in technology have made possible the treatment of a growing number of structural cardiovascular diseases by catheter based procedures. Atrial septal defects (ASD), ventricular septal defects (VSD), aortic aneurysm, congenital defects and valve disease are all currently being treated with catheter based strategies. These procedures are complex and are prone to device misplacement, e ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Nucleotide inhibitors as precision medicine in breast cancer
SBC: RECOMBINATION THERAPEUTICS LLC Topic: 102Breast cancer is the most frequently diagnosed cancer in women, and 15-20% of patients have triple negative breast cancer (TNBC) which results in a 70% mortality rate within 5 years of diagnosis. 10-15% of TNBC patients possess heritable mutations in the BRCA1/BRCA2 tumor suppressor genes which promote homologous recombination (HR) of DNA double-strand breaks (DSBs). BRCA-mutated cells are highly ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel AMPK Activators for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
SBC: NephroDI Therapeutics, Inc. Topic: 400PROJECT SUMMARYNephrogenic diabetes insipidus (NDI) is a disease characterized by the production of very large quantities of dilute urine from an inability of the kidney to respond to vasopressin. NDI can be either congenital or acquired. Acquired NDI is a common side effect of lithium therapy. Lithium-induced NDI patients produce over 3 L/d of dilute urine. Lithium is the first-line treatment for ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Functionalized perfluorocarbon nanoemulsions for enhanced cell labeling for fluorine-19 MRI detection
SBC: CELSENSE, INC. Topic: NIBIBThis project aims to develop and commercialize a novel MRI probe technology for the cell therapy tools market. This project will transfer technology invented in the academic lab of Dr. Ahrens at UCSD, to Celsense, Inc., an established company that offers imaging agents for visualizing and quantifying the trafficking of cell therapies and inflammation in the body using magnetic resonance imaging (M ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Improving data capture in clinical research using a chatbot
SBC: Dokbot, LLC Topic: NLMPROJECT SUMMARY . Collecting complete and accurate outcome data directly from research participants is becoming increasingly important. Clinical researchers needs a cost-effective approach to capture high-quality patient-reported outcomes. Typically, data captured directly from participants is through self-administered questionnaires or through a human interviewer, each with their own advantages ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Enabling membrane protein structural analysis: Tools for capillary diffusion crystallization and remote in situ diffraction experiments
SBC: Elk Valley Enterprises, Inc. Topic: 400Project SummaryThis proposal is to develop an integrated capillary counter diffusion-based approach to in situ collection of macromolecule diffraction data. The method to be developed will enable both cryogenic and ambient temperature data collection, with the latter being critical to structure-based drug design. The approach is based on a capillary that is pre-mounted in a holder that facilitates ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Nature-inspired Aqueous Biodegradable Adhesives for Abdominoplasty
SBC: ALEO BME INC Topic: NIBIBProject Summary Seroma is the most common adverse effect of many surgical procedures and is estimated to occur in up to half of all abdominoplasties. Because abdominoplasty is one of the most commonly performed aesthetic procedures in the United States (150,000/year) seroma formation is a major concern. Problems related to seroma accumulation include patient discomfort, incisional disruption and s ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Advancing Small Molecule Read Through Compounds to Prevent and/or Treat Heritable Pulmonary Artery Hypertension
SBC: ADVENT THERAPEUTICS INC Topic: NHLBIAdvent Therapeutics is a company that develops new therapies for neonatal, pediatric, and Orphan Drug “niche” markets to address serious unmet medical needs. Our team proposes early stage development of a new treatment for hereditable pulmonary arterial hypertension (hPAH), a rare, hereditary disorder that involves progressive elevation of pulmonary arterial pressures, right heart failure, and ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of a prototype software for automated PET/CT interpretation and reporting in thoracic cancer
SBC: Quantitative Radiology Solutions LLC Topic: 102Abstract. In cancer, body-wide FDG-PET/CT is a prime modality for diagnosis, staging, and treatment assessment. Despite its paramount importance to enable precision medicine in cancer, no method is currently available for automated disease burden estimation and standardized reporting on PET/CT images regionally and globally in anatomic organs and lymph node zones within a body region or body-wide. ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health